Since 2016 we have been researching and refining the methodology of microbiota transfer; our protocols are grounded in the experience of tens of thousands of capsules used.
Every successful service is backed by a well-assembled team. We are the only company in Europe to provide lyophilized human microbiota for clinical trials and sports medicine procedures. Our aim is to keep our company innovative and to deliver the required formulation to every healthcare institution in Europe within 72 hours. We not only collect and organise the expertise that reaches us, but also make this knowledge available in a systematic way, as back-up for our colleagues in patient care.
As head of the MicroBiome Bank laboratory, my role is the safe introduction of the latest microbiological technologies, which help our company ensure that the institutions we serve can deliver the highest quality and safest service during microbiota transfer.
In line with MicroBiome Bank's strategy, my primary role is the professional support of colleagues performing microbiota transfer and transplantation in institutions. Day to day, I distinguish between side effects arising during treatment and symptoms independent of the therapy.
As an intensive care physician, I maintain relationships with hospitals and outpatient clinics, providing colleagues with up-to-date information on the application of microbiota transfer and transplantation, with particular focus on CD infections.
My primary role is shaping the company's strategy, reconciling the latest research findings and legal requirements related to microbiota transplantation and transfer, and keeping patient care and educational institutions supplied with up-to-date information.
Have a question about the clinical application of microbiota transfer? Drawing on our expertise, we deliver the most advanced solutions.
Get in touch →